Posts

Posted on

Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema

Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications

Reinforces Pharming’s commitment to the HAE community and utilizes its relevant clinical expertise and global commercialization infrastructure

Companies to host joint investor call at 8:00 a.m. EDT / 2:00 p.m. CEST

BOSTON, LONDON and LEIDEN, The Netherlands, July 01, 2021 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global, commercial stage biopharmaceutical company, today announced a strategic collaboration to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of hereditary angioedema (HAE), a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen.

OTL-105 is an investigational HSC gene therapy designed to increase C1 esterase inhibitor (C1-INH) in HAE patient serum to prevent hereditary angioedema attacks. OTL-105 inserts one or more functional copies of the SERPING1 gene into patients own HSCs ex vivo which are then transplanted back into the patient for potential durable C1-INH production. In preclinical studies, to date, OTL-105 demonstrated high levels of SERPING1 gene expression via lentiviral-mediated transduction in multiple cell lines and primary human CD34+ HSCs. Furthermore, the program achieved production of functional C1-INH protein, as measured by a clinically validated assay.

Under the terms of the collaboration, Pharming has been granted worldwide rights to OTL-105 and will be responsible for clinical development, regulatory filings, and commercialization of the investigational gene therapy, including associated costs. Orchard will lead the completion of IND-enabling activities and oversee manufacturing of OTL-105 during pre-clinical and clinical development, which will be funded by Pharming. In addition, both companies will explore the application of non-toxic conditioning regimen for use with OTL-105 administration.

Orchard will receive an upfront payment of $17.5 million comprising $10 million in cash and a $7.5 million equity investment from Pharming at a premium to Orchard’s recent share price. Orchard is also eligible to receive up to $189.5 million in development, regulatory and sales milestones as well as mid-single to low double-digit royalty payments on future worldwide sales.

“Given the combination of our expertise in HSC gene therapy with Pharming’s long-standing legacy and experience, we have the potential to reinvent the treatment paradigm for HAE by providing people living with this life-threatening disorder a sustained therapy with a single administration,” said Bobby Gaspar, M.D., Ph.D., chief executive officer of Orchard Therapeutics. “This collaboration demonstrates the promise of the HSC gene therapy platform and how it can be applied to new therapeutic areas with larger patient populations. We believe the HSC gene therapy pipeline we are building could continue to be a source of future partnerships in areas where the biology supports our approach.”

“Pharming has been committed to the HAE community for more than two decades,” said Sijmen de Vries M.D., MBA, chief executive officer of Pharming. “We have partnered with Orchard Therapeutics, a leader in the development of autologous HSC gene therapy, to develop a potentially curative treatment for HAE. Based on Pharming’s experience in HAE, we believe that HSC gene therapy has the potential for the highest probability of success. This confidence is based on the durability of effect and safety observed in approved treatments from Orchard’s HSC gene therapy portfolio and positive clinical data in several other programs. This a significant first step in developing a potentially transformative one-time treatment for HAE.”

“Great progress has been made in HAE treatment over the last 15 years. However, HAE remains a severe, debilitating disease with an ongoing burden of angioedema attacks or chronic medication use,” said Dr. Marc Riedl, professor of medicine and clinical director of the U.S. Hereditary Angioedema Association Center at the University of California, San Diego. “This promising work toward treatment with the potential for durable long-term clinical benefit is encouraging and signifies an ongoing commitment to the HAE community. I look forward to these efforts to identify and carefully advance a potential cure for HAE.”

The HAE market is expected to generate ~$2 billion in sales in 2021, currently growing at 8% per annum. This represents a significant commercial opportunity for Pharming Group and Orchard Therapeutics.

Webcast Link:


https://webcast.openbriefing.com/pharming-jul21/
 

Participant Dial-in Details:
United Kingdom     0800 640 6441
United Kingdom (Local)     020 3936 2999
United States (Local)     1 646 664 1960
Netherlands     085 888 7233
All other locations     +44 20 3936 2999

Access code: 470719

About HAE

Hereditary angioedema (HAE) is a rare genetic disorder. The condition is caused by a deficiency of the C1 esterase inhibitor protein, which is normally present in blood and helps control inflammation (swelling) and parts of the immune system. Deficient C1 inhibitor does not adequately perform its regulatory function and, as a result, a biochemical imbalance can occur and produce unwanted peptides that induce the capillaries to release fluids into surrounding tissue, thereby causing swelling or edema.

HAE is characterized by spontaneous and recurrent episodes of swelling (edema attacks) of the skin in different parts of the body, as well as in the airways and internal organs. Edema of the skin usually affects the extremities, the face, and the genitals. Patients suffering from this kind of edema often withdraw from their social lives because of the disfiguration, discomfort and pain these symptoms may cause. Almost all HAE patients suffer from bouts of severe abdominal pain, nausea, vomiting and diarrhea caused by swelling of the intestinal wall.

Edema of the throat, nose or tongue is particularly dangerous and potentially life-threatening as it can lead to obstruction of the airway passages. Although there is currently no known cure for HAE, it is possible to treat the symptoms associated with angioedema attacks. HAE affects about 1 in 10,000 to 1 in 50,000 people worldwide. Experts believe a lot of patients are still seeking the right diagnosis: although HAE is (in principle) easy to diagnose, it is frequently identified very late or not discovered at all. The reason HAE is often misdiagnosed is because the symptoms are similar to those of many other common conditions such as allergies or appendicitis. By the time it is diagnosed correctly, the patient has often been through a long ordeal.

About Pharming Group N.V.

Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

The flagship of our portfolio is our recombinant human C1 esterase inhibitor (rhC1INH) franchise. C1INH is a naturally occurring protein that down regulates the complement and contact cascades in order to control inflammation in affected tissues.

Our lead product, RUCONEST®, is the first and only plasma-free rhC1INH protein replacement therapy. It is approved for the treatment of acute hereditary angioedema (HAE) attacks. We are commercializing RUCONEST® in the United States, the European Union and the United Kingdom through our own sales and marketing organization, and the rest of the world through our distribution network.

In addition, we are investigating the clinical efficacy of rhC1INH in the treatment of further indications, including pre-eclampsia, acute kidney injury, and severe pneumonia as a result of COVID-19 infections.

Furthermore, we are leveraging our transgenic manufacturing technology to develop next-generation protein replacement therapies, most notably for Pompe disease, which is currently in preclinical development.

About Orchard Therapeutics

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by severe diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Availability of Other Information About Orchard Therapeutics

Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchard’s investor relations website and may include additional social media channels. The contents of Orchard’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Orchard Therapeutics Forward-looking Statements

This press release contains certain forward-looking statements about Orchard’s strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchard’s business strategy and goals, the therapeutic potential of Orchard’s product candidates, including the product candidate or candidates referred to in this release, and the possibility of future milestone or royalty payments. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchard’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements.  In particular, these risks and uncertainties include, without limitation: the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchard’s product candidates, will be insufficient to support regulatory submissions or marketing approval in the US or EU, as applicable, or that long-term adverse safety findings may be discovered; the risk that any one or more of Orchard’s product candidates, including the product candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchard’s ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the delay of any of Orchard’s regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchard’s product candidates or the receipt of restricted marketing approvals; the inability or risk of delays in Orchard’s ability to commercialize its product candidates, if approved, or Libmeldy in the EU; the risk that the market opportunity for Libmeldy, or any of Orchard’s product candidates, may be lower than estimated; the risk that certain milestones may never be achieved or royalty payments may never be earned and paid; and the severity of the impact of the COVID-19 pandemic on Orchard’s business, including on clinical development, its supply chain and commercial programs.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading “Risk Factors” in Orchard’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, as filed with the U.S. Securities and Exchange Commission (SEC), as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchard’s views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Pharming Group N.V. Forward-looking Statements

This press release contains forward-looking statements, including with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, Pharming’s ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of its business, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2020 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release.

Inside Information

This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Orchard Therapeutics Contacts

Investors

Renee Leck
Director, Investor Relations
+1 862-242-0764
[email protected]

Media

Benjamin Navon
Director, Corporate Communications
+1 857-248-9454
[email protected]

Pharming Group N.V. Contacts

Company

Pharming Group, Leiden, The Netherlands

Sijmen de Vries,
CEO
+31 71 524 7400

Investors

Susanne Embleton
Investor Relations Manager
+31 71 524 7400
[email protected]

Media

FTI Consulting, London, UK

Victoria Foster Mitchell/Alex Shaw
+44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands

Leon Melens
+31 6 53 81 64 27
[email protected]



Posted on

EverCommerce Announces Pricing of Initial Public Offering

DENVER, July 01, 2021 (GLOBE NEWSWIRE) — EverCommerce Inc. (“EverCommerce”), a leading service commerce platform, announced today the pricing of its initial public offering of 19,117,648 shares of its common stock at a public offering price of $17.00 per share. The shares are expected to begin trading on the NASDAQ Global Select Market on July 1, 2021, under the ticker symbol “EVCM.” The initial public offering is expected to close on July 6, 2021, subject to customary closing conditions.

In addition, the underwriters have been granted a 30-day option to purchase up to an additional 2,867,647 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

In addition to the shares of common stock sold in the public offering, EverCommerce announced that entities affiliated with Silver Lake, an existing stockholder, will purchase 4,411,764 shares of common stock in a private placement at a price per share equal to the initial public offering price, subject to customary closing conditions. The sale of these shares will not be registered under the Securities Act of 1933, as amended. The closing of the initial public offering is not conditioned upon the closing of the private placement.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, RBC Capital Markets, LLC and KKR Capital Markets LLC are acting as lead book-running managers for the initial public offering. Barclays Capital Inc., Deutsche Bank Securities Inc., Jefferies LLC, Evercore Group L.L.C, Oppenheimer & Co. Inc., Piper Sandler & Co., Raymond James & Associates, Inc. and Stifel, Nicolaus & Company, Incorporated are also acting as bookrunners for the initial public offering. Canaccord Genuity LLC, JMP Securities LLC, Academy Securities, Inc., Loop Capital Markets LLC, R. Seelaus & Co., LLC and Samuel A. Ramirez & Company, Inc. are acting as co-managers for the initial public offering.

A registration statement relating to the shares being sold in the initial public offering was declared effective by the Securities and Exchange Commission on June 30, 2021. The initial public offering is being made only by means of a prospectus. Copies of the final prospectus relating to this initial public offering, when available, may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, collect telephone: 1-212-834-4533, or by emailing at [email protected]; or RBC Capital Markets, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About EverCommerce:

EverCommerce is a leading service commerce platform, providing vertically-tailored, integrated SaaS solutions that help more than 500,000 service-based businesses accelerate growth, streamline operations, and increase retention. Its modern digital and mobile applications create predictable, informed, and convenient experiences between service professionals and their end consumers. Specializing in Home Services, Health Services, and Fitness & Wellness Services industries, EverCommerce solutions include end-to-end business management software, integrated payment acceptance, marketing technology, and customer engagement applications.

Press Contact:

Brunswick Group
Darren McDermott / Patricia Graue
T: +1 (917) 345-3621 / +1 (415) 990-8039
E: [email protected]

Investor Relations Contact:

ICR, LLC for EverCommerce
Brian Denyeau
T: +1 (646) 277-1251
E: [email protected]



Posted on

Dr. Reddy’s Laboratories Announces Filing of Annual Report on Form 20-F

Dr. Reddy’s Laboratories Announces Filing of Annual Report on Form 20-F

HYDERABAD, India–(BUSINESS WIRE)–
Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that its Annual Report on Form 20-F containing its consolidated financial statements for the fiscal year ended March 31, 2021 and prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board was filed with the United States Securities and Exchange Commission (SEC) on June 30, 2021.

The Annual Report on Form 20-F is also available on the website of Dr. Reddy’s, www.drreddys.com. American Depositary Receipts (ADRs) holders may also obtain a hard copy of the Annual Report on Form 20-F at no cost, by sending a written request to the Company’s registered office or by sending an e-mail to [email protected].

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to:www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.”

INVESTOR RELATIONS

AMIT AGARWAL

[email protected]

MEDIA RELATIONS

USHA IYER

[email protected]

KEYWORDS: United States India North America Asia Pacific New York

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo
Posted on

Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering

CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes to be a key underlying cause of Alzheimer’s disease, today announced the pricing of its upsized initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to Acumen, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $160 million. All of the shares of common stock are being offered by Acumen. In addition, Acumen has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Acumen’s shares are expected to begin trading on the Nasdaq Global Select Market on Thursday, July 1, 2021 under the ticker symbol “ABOS.” The offering is expected to close on July 6, 2021, subject to customary closing conditions.

BofA Securities, Credit Suisse and Stifel are acting as joint lead book-running managers for the offering. UBS Investment Bank is also acting as a book-running manager.

A registration statement relating to the shares being sold in this offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on June 30, 2021. The offering of the shares is being made only by means of a prospectus forming part of the effective registration statement relating to these shares. Copies of the final prospectus, when available, may be obtained from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [email protected]; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, or by telephone at (800) 221-1037 or by email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Acumen Pharmaceuticals

Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding Acumen’s expectations regarding the commencement of trading of its shares on the Nasdaq Global Select Market, the completion and timing of the closing of offering and the anticipated use of net proceeds from the offering. Forward-looking statements are based on Acumen’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in biopharmaceutical product development and clinical trials. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the offering to be filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acumen undertakes no duty to update such information except as required under applicable law.

Investor Contact:

[email protected]



Posted on

Torrid Holdings Inc. Announces Pricing of Initial Public Offering

Torrid Holdings Inc. Announces Pricing of Initial Public Offering

CITY OF INDUSTRY, Calif.–(BUSINESS WIRE)–
Torrid Holdings Inc. (“Torrid” or the “Company”) today announced the pricing of its initial public offering of 11.0 million shares of its common stock to be sold by certain of Torrid’s existing shareholders at a price of $21.00 per share. In addition, the selling shareholders have granted the underwriters a 30-day option to buy an additional 1.65 million shares of common stock from such selling shareholders at the initial public offering price, less the underwriting discount and commissions. Torrid will not receive any proceeds from the sale of the shares by the selling shareholders. The shares are expected to begin trading on the New York Stock Exchange (“NYSE”) on July 1, 2021, under the ticker symbol “CURV”. The offering is expected to close on July 6, 2021, subject to customary closing conditions.

Morgan Stanley, BofA Securities, Inc., Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint lead book-running managers for the offering. Baird, Cowen and William Blair are acting as joint book-running managers for the offering. Telsey Advisory Group LLC is acting as a co-manager for the offering.

The initial public offering is being made only by means of a prospectus. When available, copies of the final prospectus related to the offering may be obtained from:

  • Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014
  • BofA Securities, Inc., Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina, 28255-0001, or by email at [email protected]
  • Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by email at [email protected]
  • Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]

A registration statement on Form S-1 relating to this offering was declared effective on June 30, 2021, by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About TORRID

TORRID is a direct-to-consumer brand of apparel, intimates and accessories in North America targeting the 25- to 40-year old woman who is curvy and wears sizes 10 to 30. TORRID is focused on fit and offers high quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear and accessories.

Forward Looking Statements

This press release contains forward looking statements, including statements regarding the initial public offering. These statements are not historical facts but rather are based on Torrid’s current expectations and projections regarding its business, operations and other factors relating thereto. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates” and similar expressions are used to identify these forward looking statements. These statements are only predictions and as such are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual results may differ materially from those in the forward looking statements as a result of a number of factors, including those in Torrid’s registration statement filed with the Securities and Exchange Commission.

Investors

ICR

Jean Fontana

646-277-1214

[email protected]

Media

Joele Frank, Wilkinson Brimmer Katcher

Leigh Parrish / Lyle Weston

(212) 355-4449

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Fashion Professional Services Retail Consumer Women Finance

MEDIA:

Posted on

Billtrust Announces Pricing of Public Offering of Common Stock

LAWRENCEVILLE, N.J., June 30, 2021 (GLOBE NEWSWIRE) — BTRS Holdings Inc. (Nasdaq: BTRS) (“Billtrust”), a leading provider of cloud-based software and integrated payment processing solutions that simplify and automate B2B commerce, today announced the pricing of an underwritten secondary offering of 9,000,000 shares of the Company’s Class 1 common stock at a public offering price of $12.25 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions, are expected to be $110,250,000. All of the Class 1 common stock is being offered by existing shareholders and Billtrust will not receive any of the proceeds from the offering. Certain selling shareholders have granted the underwriters a 30-day option to purchase an aggregate of not more than 1,350,000 additional shares of the Company’s Class 1 common stock on the same terms and conditions. The Company will not receive any proceeds from any sale of shares by the selling shareholders.

The offering is expected to close on or about July 6, 2021, subject to satisfaction of customary closing conditions.

Citigroup Global Markets, Inc., J.P. Morgan Securities LLC, BofA Securities, Inc. and William Blair & Company, L.L.C. are acting as bookrunners. Canaccord Genuity LLC, Guggenheim Securities, LLC and Needham & Company, LLC are acting as co-managers.

A registration statement on Form S-1 relating to the shares being sold in this offering, including a prospectus, was filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 28, 2021, and became effective on June 30, 2021. A prospectus relating to the offering is available for free on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-800-831-9146; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 1-866-803-9204; email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BTRS Holdings Inc.

Billtrust is at the forefront of the digital transformation of accounts receivable (“AR”), providing mission-critical solutions that span credit decisioning and monitoring, online ordering, invoicing, cash application, and collections. Billtrust solutions integrate with a number of ecosystem players, including financial institutions, enterprise resource planning (“ERP”) systems, and accounts payable (“AP”) software platforms, to help customers accelerate cash flow and generate sales more quickly and efficiently. Customers use the Billtrust platform to transition from expensive paper invoicing and check acceptance to efficient electronic billing and payments, which accelerates revenue capture, generates cost savings, and provides a better user experience.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “continue,” “goal,” “project” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Billtrust’s financial and business performance, changes in Billtrust’s strategy, the potential benefits to Billtrust’s customers of Billtrust’s services, Billtrust’s opportunity and ability to grow and scale its business, Billtrust’s expansion plans, the impact of health epidemics on Billtrust’s business, and future operating results. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Billtrust’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of Billtrust. These forward-looking statements are subject to a number of risks and uncertainties, including the ability to maintain the listing of Billtrust common stock on Nasdaq; changes in applicable laws and regulations; the impact of the COVID-19 pandemic on Billtrust’s business; Billtrust’s ability to execute its business model, Billtrust’s ability to attract and retain customers and expand customers’ use of Billtrust’s products and services; risks relating to the uncertainty of Billtrust’s projected financial and operating information; Billtrust’s ability to raise capital; the possibility Billtrust will be adversely affected by other economic, business, and/or competitive factors; and the risks discussed in Billtrust’s Annual Report on Form 10-K filed on March 24, 2021, under the heading “Risk Factors” and other documents of Billtrust filed, or to be filed, with the SEC. If any of these risks materialize or any of Billtrust’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Billtrust presently does not know of or that Billtrust currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Billtrust’s expectations, plans or forecasts of future events and views as of the date of this press release. Billtrust anticipates that subsequent events and developments will cause Billtrust’s assessments to change. However, while Billtrust may elect to update these forward-looking statements at some point in the future, Billtrust specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Billtrust’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Investor Relations Contact for Billtrust:

ICR
[email protected]

Media Contact for Billtrust:

Meredith Simpson
[email protected]
www.billtrust.com



Posted on

Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of $19.00 per share. In addition, Aligos has granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of common stock at the same terms and conditions. All of the shares of common stock are being offered by Aligos. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aligos, are expected to be approximately $83.6 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on July 6, 2021, subject to customary closing conditions.

J.P. Morgan, Jefferies and Piper Sandler are acting as the joint book-running managers for the offering. Cantor is acting as a lead manager for the offering.

A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on June 30, 2021. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected] or by telephone at (866) 803-9204, or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected], or from Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos s focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond Aligos’ control. These statements include statements regarding the completion and timing of the closing of the public offering. These statements involve risks and uncertainties, including, without limitation, the uncertainties inherent in the drug development process, regulatory approval processes, and the challenges associated with manufacturing drug products, as well as risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the public offering. Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the forward-looking statements. For a further description of the risks and uncertainties relating to Aligos’ business in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021, the preliminary prospectus for this offering included as part of the Registration Statement on Form S-1 related to the offering filed with the SEC on June 28, 2021, and its future periodic reports to be filed with the SEC. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Media Contact

Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
[email protected]

Investor Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]



Posted on

Realty Income Announces Pricing Of Upsized 8.0 Million Share Common Stock Offering

PR Newswire

SAN DIEGO, June 30, 2021 /PRNewswire/ — Realty Income Corporation (Realty Income, NYSE: O), The Monthly Dividend Company®, today announced the pricing of an underwritten public offering of 8,000,000 shares of the company’s common stock for expected gross proceeds of approximately $519 million. The offering is expected to close on July 6, 2021. The underwriters of the offering have been granted a 30-day option to purchase up to 1,200,000 additional shares of common stock. The joint book-running managers for the offering are Wells Fargo Securities and Morgan Stanley.

The company intends to use net proceeds from the offering to repay borrowings under its $3.0 billion revolving credit facility and/or $1.0 billion commercial paper program, and, to the extent not used for that purpose, to fund potential investment opportunities and/or for other general corporate purposes.

A prospectus supplement and accompanying prospectus related to the public offering of these securities will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and the accompanying prospectus, when available, may be obtained from Wells Fargo Securities, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at (800) 326-5897 or email: [email protected]; or Morgan Stanley, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014.

These securities are offered pursuant to a Registration Statement that has become effective under the Securities Act. These securities are only offered by means of the prospectus supplement related to the offering and the related prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer or sale of these securities, in any state or other jurisdiction where, or to any person to whom, the offer, solicitation, or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.


Forward-Looking Statements

Statements in this press release that are not strictly historical are “forward-looking” statements. Forward-looking statements involve known and unknown risks, which may cause the company’s actual future results to differ materially from expected results. These risks include, among others, general economic conditions, domestic and foreign real estate conditions, client financial health, the availability of capital to finance planned growth, volatility and uncertainty in the credit markets and broader financial markets, changes in foreign currency exchange rates, property acquisitions and the timing of these acquisitions, the structure, timing and completion of the announced mergers between us and VEREIT, Inc., if consummated, and any effects of the announcement, pendency or completion of the announced mergers, including the anticipated benefits therefrom, charges for property impairments, the effects of the COVID-19 pandemic and the measures taken to limit its impact, or the effects of other pandemics or global outbreaks of contagious diseases or fear of such outbreaks, on the company’s clients’ ability to adequately manage their properties and fulfill their respective lease obligations to the company, and the outcome of any legal proceedings to which the company is a party, as described in the company’s filings with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as reflections of the company’s current operating plans and estimates. Actual operating results may differ materially from what is expressed or forecast in this press release. The company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date these statements were made.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/realty-income-announces-pricing-of-upsized-8-0-million-share-common-stock-offering-301323825.html

SOURCE Realty Income Corporation

Posted on

Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the pricing of its upsized underwritten public offering of 4,755,000 shares of its common stock at a public offering price of $47.00 per share. All shares are being offered by Kymera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $223.5 million. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 713,250 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on July 6, 2021, subject to the satisfaction of customary closing conditions.

Morgan Stanley, J.P. Morgan, Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering.

A registration statement relating to the sale of these securities has been filed with, and declared effective by, the Securities and Exchange Commission (“SEC”). The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering, when available, may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or via email at [email protected]; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attention: Prospectus Department, by telephone at (833) 297-2926; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

About Kymera Therapeutics

Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera’s goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.

Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.”

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding Kymera’s expectations regarding the completion and timing of the closing of the offering and the anticipated gross proceeds from the offering. Forward-looking statements are based on Kymera’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in biopharmaceutical product development and clinical trials. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Quarterly Report on Form 10-Q for the period ended March 31, 2021 filed on May 6, 2021, as well as discussions of potential risks, uncertainties and other important factors in the final prospectus related to this offering. Forward-looking statements contained in this announcement are made as of this date, and Kymera undertakes no duty to update such information except as required under applicable law.

Contact:

Paul Cox
VP, Investor Relations and Communications
[email protected]
917-754-0207



Posted on

Walmart Wraps Annual Open Call Event, 167 Products to Advance, 705 to Receive Further Consideration

Walmart Wraps Annual Open Call Event, 167 Products to Advance, 705 to Receive Further Consideration

Company shares more details on “American Lighthouses” concept, designed to overcome barriers to U.S. production, will focus on key categories, starting with textiles

BENTONVILLE, Ark.–(BUSINESS WIRE)–
Open Call 2021 is now in the books with more than 900 small businesses from across the country pitching their products made, grown or assembled in the U.S. to Walmart and Sam’s Club merchants today. As expected, this year’s cohort marked the largest number of business owners ever to take part in the one-day event, representing all 50 states, the District of Columbia and Puerto Rico. Of those businesses, 167 of their products are advancing to the next stage in the process to land a deal with Walmart or Sam’s Club and another 705 are receiving further consideration. During this year’s virtual Open Call event, small businesses also learned more about Walmart’s “American Lighthouses,” a plan to unite key stakeholders in specific regions of the country to identify and overcome top-down barriers to U.S. production.

“Open Call supports Walmart’s overall commitment to U.S manufacturing and small businesses. In March, we announced an additional spend of $350 billion on items made, grown or assembled in the U.S. over the next ten years,” said Laura Phillips, senior vice president, customer and business development and U.S. manufacturing for global sourcing at Walmart. “We also announced our American Lighthouses concept, which strives to accelerate progress on this commitment. To do this, we aim to bring together key regions and various stakeholders to address obstacles, support and pilot innovative projects and provide tools and resources for businesses to invest in U.S. production, making the supply chain more efficient, sustainable and making it easier for U.S. manufacturing to flourish.”

Walmart’s American Lighthouses concept will focus on these categories: textiles; metals and motors; food processing; plastics; pharmaceutical and medical supplies. During Open Call today, the retailer shared that textiles will be the first focus area for Lighthouses.

“We are inspired and excited by Walmart’s American Lighthouses concept and agree that U.S. manufacturing is critical, sustainable and achievable through collaborative efforts across multiple stakeholders,” said Peter Senger, senior vice president/general manager, merchandising, marketing and sales at Renfro Brands, a leading producer of socks and legwear products located in North Carolina. “We employ about 2,000 people across the U.S. and working with Walmart has allowed us to continue to support the needs of the American worker. We believe that an investment in American jobs is an investment that provides for American families and strengthens the communities they live in with a stable and sustainable way of life.”

Open Call supports Walmart’s overall $350 billion commitment to U.S. Manufacturing. In addition to an increase in spending and support for small businesses and diverse suppliers through efforts like Open Call, the company estimates the commitment will support the creation of more than 750,000 new American jobs and will help avoid 100 million metric tons of CO2 emissions by sourcing closer to customers.

Businesses who advanced during Open Call today will now work with merchants on opportunities to sell their products in Walmart stores and Sam’s Clubs. All businesses who took part in Open Call are eligible to sell their shelf-stable products on Walmart’s various online platforms Walmart.com, Walmart Marketplace or Samsclub.com.

The day kicked off with a General Session in which the business owners heard from guest celebrity – and current Walmart vendor – Jay Leno, who encouraged businesses and entrepreneurs to make the perfect pitch by bringing their “A” game, looking Walmart merchants in the eye and delivering more than they promise.

Governors from Utah, Colorado, Georgia, Ohio, Missouri, Indiana and Arkansas also joined in to thank small business and Walmart for supporting U.S. manufacturing.

The General Session was hosted by Tony Waller, vice president constituent relations and racial equity – Walmart U.S. Other Walmart leaders, including Doug McMillon, president and CEO – Walmart Inc., and John Furner, president and CEO – Walmart U.S., also spoke to the business owners.

About Walmart

Walmart Inc. (NYSE: WMT) helps people around the world save money and live better – anytime and anywhere – in retail stores, online, and through their mobile devices. Each week, approximately 220 million customers and members visit approximately 10,500 stores and clubs under 48 banners in 24 countries and eCommerce websites. With fiscal year 2021 revenue of $559 billion, Walmart employs 2.2 million associates worldwide. Walmart continues to be a leader in sustainability, corporate philanthropy and employment opportunity. Additional information about Walmart can be found by visiting https://corporate.walmart.com, on Facebook at https://facebook.com/walmart and on Twitter at https://twitter.com/walmart.

Walmart Media Relations

1-800-331-0085

news.walmart.com/reporter

KEYWORDS: Arkansas United States North America

INDUSTRY KEYWORDS: Women Textiles Department Stores Men Other Retail Chemicals/Plastics Automotive Manufacturing Family Supermarket Manufacturing Consumer Food/Beverage Pharmaceutical Retail Environment Small Business Professional Services Home Goods Health Other Consumer Online Retail

MEDIA: